Acotiamide

Summary

Acotiamide (CHEMBL2107723) is a phase-3 clinical-stage small molecule (ATC A03FA10); indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A03FA10
• Indications: 1 condition
• Clinical trials: 4
• Chemistry: 450.6 Da · C21H30N4O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107723
Name	Acotiamide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5282338
ATC	A03FA10
Molecular formula	C21H30N4O5S
Molecular weight	450.6
InChIKey	TWHZNAUBXFZMCA-UHFFFAOYSA-N

SMILES: CC(C)N(CCNC(=O)C1=CSC(=N1)NC(=O)C2=CC(=C(C=C2O)OC)OC)C(C)C

IUPAC name: N-[2-[di(propan-2-yl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide

Also known as: Acotiamida, Acotiamide, ACOTIAMIDE

Parent form; salt/anhydrous children: CHEMBL2107308, CHEMBL5414074

Patent coverage: 87 distinct patent families (215 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 212 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Acetylcholinesterase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ACHE	5.52	IC50	3000	nM	CHEMBL_ACT_25969741

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
Not specified	2
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07449689	PHASE4	NOT_YET_RECRUITING	Comparing Acotiamide and Itopride for the Management of Indigestion
NCT07174297	PHASE3	NOT_YET_RECRUITING	Acotiamide vs Itopride in Postprandial Distress Syndrome
NCT03402984	Not specified	COMPLETED	Effect of Acotiamide on Gastric Motility and Satiation in Healthy Volunteers
NCT04697641	Not specified	COMPLETED	Helicobacter Pylori Eradication in Functional Dyspepsia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).